



June 6, 2019

## PRODUCT SUPPLY UPDATE - ONCOLOGY

### **<sup>Pr</sup>FLUDARABINE PHOSPHATE FOR INJECTION, 25 mg/mL, DIN 02283859**

Dear Healthcare Provider,

Fludarabine phosphate for injection is indicated for second line treatment in patients with chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin's lymphoma (Lg-NHL) who have failed other conventional therapies (*Product Monograph, Teva Canada Limited, March 1, 2016*).

#### **Current supply status and allocation strategy**

<b>Product</b>	<b>Current Months of Supply<sup>1</sup></b>	<b>Allocation Filter in Place<sup>2</sup></b>	<b>Alternate Sources<sup>3</sup></b>
2 mL single use vial	2	Up to 50%	Injectable: None Oral Tablets: <sup>Pr</sup> Fludara <sup>®</sup>

<sup>1</sup> Represents combined current stock on hand at wholesalers and at Teva

<sup>2</sup> All orders will be allocated based on historical demand, please contact your Key Account Manager for assistance

<sup>3</sup> <sup>Pr</sup>Fludara<sup>®</sup> (fludarabine phosphate tablets 10 mg) is a registered trademark exclusively licensed to Genzyme Corporation (marketed by sanofi-aventis Canada Inc.)

Our expected replenishment has been delayed to approximately Q4 2019 due to delays in receiving the active pharmaceutical ingredient (API) at our manufacturing facility. We continue to work with our global supply chain to accelerate this date with the aim of improving longer term coverage.

Thank you for your understanding and continued support.

Hospital Division  
Teva Canada Limited